Humacyte, Inc. ( HUMA ) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -73.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Humacyte Posts Q2 Revenue Miss
Humacyte ( NASDAQ:HUMA ) , a regenerative medicine company focused on bioengineered human tissues, released its Q2 FY2025 earnings on August 11, 2025. The most notable news from the release was the company's continued operational progress with its lead product Symvess, which saw growing hospital ...
Humacyte, Inc. ( HUMA ) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) concluded the recent trading session at $2.21, signifying a -4.33% move from its prior day's close.
Humacyte, Inc. ( HUMA ) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.
Humacyte, Inc. ( HUMA ) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.
Humacyte, Inc. ( HUMA ) Stock Falls Amid Market Uptick: What Investors Need to Know
Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Arrowhead Pharma ( NASDAQ:ARWR ) , Abivax ( NASDAQ:ABVX )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of GE Vernova Inc. GEV rose sharply during Wednesday's session after the company posted better-than-expected second-quarter 2025 earnings and raised its full-year guidance.
Humacyte Announces First Symvess™ Sale to Military Treatment Facility - Humacyte ( NASDAQ:HUMA )
Sale follows recent Electronic Catalog ( ECAT ) listing approval by U.S. Defense Logistics Agency Symvess now available to U.S. Department of Defense and U.S. Department of Veterans Affairs facilities DURHAM, N.C., July 23, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc.
Humacyte, Inc. ( HUMA ) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) concluded the recent trading session at $2.33, signifying a -3.72% move from its prior day's close.
Why Humacyte, Inc. ( HUMA ) Dipped More Than Broader Market Today
Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.
Humacyte, Inc. ( HUMA ) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.
Gold Falls 1%; ProKidney Shares Spike Higher - Apogee Therapeutics ( NASDAQ:APGE ) , Blue Gold ( NASDAQ:BGL )
U.S. stocks traded mixed midway through trading, with the Dow Jones index dipping more than 150 points on Tuesday. The Dow traded down 0.35% to 44,249.09 while the NASDAQ gained 0.07% to 20,427.63. The S&P 500 also fell, dropping, 0.03% to 6,228.39. Energy shares jumped by 2.1% on Tuesday.
Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Humacyte, Inc. ( HUMA ) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.
Humacyte, Inc. ( HUMA ) Stock Moves -1.79%: What You Should Know
In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.19, marking a -1.79% move from the previous day.
Humacyte, Inc. ( HUMA ) Gains As Market Dips: What You Should Know
Humacyte, Inc. (HUMA) concluded the recent trading session at $2.36, signifying a +1.29% move from its prior day's close.
Is Humacyte, Inc. ( HUMA ) a Buy as Wall Street Analysts Look Optimistic?
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
DURHAM, N.C., May 19, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc. ( Nasdaq: HUMA ) , a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and ...
Humacyte, Inc. ( HUMA ) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 47.37% and 2.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
- Commenced market launch and first commercial sales of Symvess™ ( acellular tissue engineered vessel-tyod ) for the treatment of extremity vascular trauma ...
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
DURHAM, N.C., May 09, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc. ( Nasdaq: HUMA ) , a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on ...
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May ...
Humacyte, Inc. ( HUMA ) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.
All You Need to Know About Humacyte, Inc. ( HUMA ) Rating Upgrade to Buy
Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Humacyte, Inc. ( HUMA ) Ascends But Remains Behind Market: Some Facts to Note
Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.
Humacyte, Inc. ( HUMA ) Increases Despite Market Slip: Here's What You Need to Know
Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.
Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000 - FormFactor ( NASDAQ:FORM ) , FTAI Aviation ( NASDAQ:FTAI )
The Russell 2000 rose over 8% on Wednesday from President Donald Trump's announced pause of tariffs. Semiconductor stocks were among the highest performing components of the index. Wall Street veteran Chris Capre is going live April 9 at 6 PM ET to reveal a short-term strategy that just returned ...
Humacyte, Inc. ( HUMA ) Stock Moves -0.68%: What You Should Know
Humacyte, Inc. (HUMA) closed at $1.45 in the latest trading session, marking a -0.68% move from the prior day.
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Received U.S. Food and Drug Administration ( FDA ) approval of Symvess™ ( acellular tissue engineered vessel-tyod ) for the treatment of extremity vascular trauma ...
Why Humacyte ( HUMA ) Stock Is Falling Sharply - Humacyte ( NASDAQ:HUMA )
Humacyte shares are trading lower by 29% during Wednesday's session. The company priced a $50 million public offering.
Brokers Suggest Investing in Humacyte, Inc. ( HUMA ) : Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Chewy ( NYSE:CHWY ) , Bausch Health Companies ( NYSE:BHC )
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Chewy, Inc. CHWY fell sharply in pre-market trading after the company reported quarterly earnings.
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert - CISO Global ( NASDAQ:CISO )
U.S. stock futures were trading lower on Wednesday, after advancing for three consecutive sessions. Futures of major benchmark indices were lower in premarket trading. Investors are reacting cautiously to President Donald Trump's mixed tariff signals.
Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - AquaBounty Techs ( NASDAQ:AQB ) , Benson Hill ( NASDAQ:BHIL )
Shares of GameStop Corp. GME rose sharply in today's pre-market trading after reporting better-than-expected fourth-quarter earnings. GameStop reported fourth-quarter revenue of $1.283 billion, missing the consensus estimate of $1.48 billion.
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock - Humacyte ( NASDAQ:HUMA )
DURHAM, N.C., March 25, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc. HUMA, a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its ...
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc. ( Nasdaq: HUMA ) , a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 ...
Humacyte Shares Plunge After Hours: Here's Why - Humacyte ( NASDAQ:HUMA )
Humacyte announces it commenced an underwritten public offering of common stock. Humacyte had $71 million in cash, cash equivalents and restricted cash as of Sept. 30, 2024.
Humacyte, Inc. ( HUMA ) Flat As Market Gains: What You Should Know
In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $3.32, denoting no change from the preceding trading day.
Humacyte, Inc. ( HUMA ) Stock Sinks As Market Gains: Here's Why
Humacyte, Inc. (HUMA) concluded the recent trading session at $2.99, signifying a -0.33% move from its prior day's close.
Humacyte Announces Publication of the Budget Impact Model ( BIM ) for Symvess™ ( acellular tissue engineered vessel-tyod ) in the Journal of Medical Economics - Humacyte ( NASDAQ:HUMA )
- Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair - - Publication of the Budget Impact Model in peer-reviewed journal supports Symvess as a treatment that provides economic value to ...
Humacyte Announces Publication of the Budget Impact Model ( BIM ) for Symvess™ ( acellular tissue engineered vessel-tyod ) in the Journal of Medical Economics
- Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair ...
Wall Street Bulls Look Optimistic About Humacyte, Inc. ( HUMA ) : Should You Buy?
Based on the average brokerage recommendation (ABR), Humacyte, Inc. (HUMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Humacyte, Inc. ( HUMA ) Stock Slides as Market Rises: Facts to Know Before You Trade
Humacyte, Inc. (HUMA) closed the most recent trading day at $3.15, moving -1.56% from the previous trading session.
Humacyte, Inc. ( HUMA ) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Humacyte, Inc. (HUMA) closed at $3.37, indicating a -1.75% shift from the previous trading day.
Humacyte Announces Commercial Launch of Symvess™ ( acellular tissue engineered vessel-tyod ) for Extremity Vascular Trauma - Humacyte ( NASDAQ:HUMA )
- The FDA has authorized Humacyte to release commercial shipments - - Positive responses from surgeons and trauma centers to initial sales and marketing outreach - - 21 hospitals have already initiated the Value Analysis Committee ( VAC ) approval process -
Humacyte, Inc. ( HUMA ) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) closed the most recent trading day at $3.96, moving -1.25% from the previous trading session.
Humacyte, Inc. ( HUMA ) Stock Sinks As Market Gains: What You Should Know
Humacyte, Inc. (HUMA) concluded the recent trading session at $4.30, signifying a -1.6% move from its prior day's close.
Humacyte, Inc. ( HUMA ) Laps the Stock Market: Here's Why
Humacyte, Inc. (HUMA) concluded the recent trading session at $4.37, signifying a +1.63% move from its prior day's close.
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas ( BVP™ ) Development Using iPSCs
DURHAM, N.C.and SEATTLE, Jan. 28, 2025 ( GLOBE NEWSWIRE ) -- Humacyte, Inc. ( Nasdaq: HUMA ) , a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, and Pluristyx, Inc. today announced an expanded partnership.
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Humacyte ( NASDAQ:HUMA )
NEW YORK, Jan. 23, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Humacyte, Inc.
